Table 2.

Patient clinical outcomes tryptase and CPA3 immunostaining

	N (% of total 29 patients)
Stage
IIIA	1 (3%)
IIIB	2 (7%)
IIIC	20 (69%)
IV	6 (21%)
Recurred
Yes	27 (93%)
No	2 (7%)
Overall Survival Status
Living	6 (20%)
Deceased	23 (80%)
	Median [Range]
Age at Diagnosis	63 [46–79]
PFS (months)	15.5 [8–51]
OS (months)	37 [12–83]